SBIR Phase I: Development of Agents to Promote Cellular Ga-67 (Gallium-67) Uptake

该小型企业创新研究（SBIR）第一阶段项目旨在开发新的药剂，以选择性地增强使用镓（Ga-67）的肿瘤成像。 Ga-67因其成本低、使用方便、寿命长等显著优势，已广泛应用于肿瘤成像和临床医学。然而，Ga-67的使用目前受到限制，主要是由于不同的肿瘤亲合力和在非镓亲合力肿瘤中实现高信号背景比所需的高剂量要求。增加肿瘤细胞对镓的选择性摄取将大大改善镓成像，从而开发出一种创新的、灵敏的、低成本的肿瘤检测工具。该第一阶段计划将专注于设计，制备和评估具有大幅增加肿瘤细胞对Ga-67的摄取潜力的新型硝普钠衍生物。该项目的商业应用是在肿瘤成像和肿瘤学领域。

This Small Business Innovation Research (SBIR) Phase I project is proposes to develop new pharmaceutical agents to selectively enhance tumor imaging using gallium (Ga-67). Ga-67 has been widely used in tumor imaging and clinical medicine due to significant advantages in terms of low cost, ease of use and long life. However, the use of Ga -67 is currently limited, mainly due to varying tumor avidity and high dose requirements needed to achieve high signal-to-background ratios in non-gallium avid tumors. Increasing the selective uptake of gallium by tumor cells will dramatically improve gallium imaging, resulting in the development of an innovative, sensitive, and low-cost tumor detection tool. This Phase I program will focus on designing, preparing and evaluating novel nitrosipine derivatives with the potential to drastically increase the uptake of Ga-67 by tumor cells. The commercial application of this project is in the area of tumor imaging and oncology.